

CardieX

Corporate Presentation

August 2022



Track What Matters



CardieX Vitals

Only Blood Pressure
Devices That Allow
Physician
Reimbursement for Full
Arterial Health
Measurements.



Immeasurable Global
Health Impact



Targeting the world's largest health market opportunities.

Market leading central blood pressure technology and IP portfolio.

Validated by leading blue-chip customers over 20-years.

Strong product development and FDA clearance pipeline - multiple "world-firsts".

"Category Creator" with data-driven go-to-market & execution strategy.

Low regulatory risk.

No direct competition.

Multiple revenue streams driving strong financial growth.

Seasoned team with extensive consumer, pharma, and medical device track records.

ATCOR



Specialized medical devices for clinical trials, research by academic institutions, and routine clinical use by specialists (e.g. cardiologists, nephrologists)

Core IP in arterial biometric parameters – all based on proprietary methods to analyze central arterial pressure waveforms.

510K-cleared "gold standard" technology with worldwide adoption.

Est 1994

CardieX

(ASX:CDX*)

Group parent company with principal USA operations and corporate domicile.

Key group technology is commercialized by ATCOR for specialized clinical use and by CONNEQT for consumer/health care use in multiple applications.



*Uplisting to US exchange.

CONNEQT



Expansion into FDA cleared devices for consumer health and HCP markets.

For consumers, patients, decentralized clinical trials, and remote patient monitoring.

"Category Creator" in vascular health.

2022 Launch

Our Focus: World's Largest Health Technology Markets



Global Remote
Patient Monitoring



\$117.1B

2025

(Forbes Communication Council)



Our Focus: World's Largest Health Markets

Total addressable
health population

2.5B Humans 



Hypertension & Cardiovascular Disease

1.3 billion hypertensives



Diabetes

578m global diabetics by 2030



Cognitive Health

44m living with Alzheimer's and dementia



Renal Disease

700m CKD cases globally

Cardiovascular (CV) disease is the

#1 Killer

of humans globally¹



The Problem: World's Biggest Healthcare Crisis

People are getting sicker while healthcare costs keep rising - CVD #1 cause of death

Total Cost of CVD Annually

\$363B
2020



\$1.1 Trillion
2035

113M



Hypertensives in the USA
(50% of US Adults)



19M

Heart Disease Deaths Globally
(1 Every 36 Seconds in USA)

33%

Global Deaths
Related to CVD




38%

Rise in Blood Pressure
Related Deaths
(2005 - 2018)

And the healthcare system is to blame

The current patient journey for hypertension is broken – it's narrowly focused with limited health data and patient education.





The Wearable Truth

“Due to validation procedures and accuracy we cannot recommend any existing wearable for use in clinical practice”

European Working Group on Hypertension
Hypertension Journal - June, 2022

Core Foundations of Our Solutions:

Maximizing health impact based on 4 principles.



Complete **Medical Grade Arterial Health Data**



SphygmoCor®

Patented Arterial and Central Blood Pressure Measurement.



Better Health Insights: **Where it Matters.**



Heart, Brain, Kidneys, Major Organs.



Clinical Validation



“Gold Standard”,
Accurate,
Trustworthy
Wearable Health
Data



Maximum Global Health & Financial Impact



Preventative Insights,
Personalized
Treatments,
Reduced Healthcare
Costs.

Our Core Technology - "Gold Standard" Central Blood Pressure Measurement.



We non-invasively extract high fidelity arterial signals from **multiple sensor formats** (pressure and PPG/wearable).



Signals are processed through our patented algorithms to extract actionable arterial health data **not available from traditional blood pressure devices and wearables.**

UNIQUE CPT Reimbursement Code: 93050

*Only FDA cleared devices for full arterial waveform analysis and reimbursement in adults.




Cuff-Based Pressure Signals

Our Core Technology

SphygmoCor[®] measures “**central blood pressure**” and other arterial biometrics at the heart and major organs* providing medical and consumer health parameters not available from traditional blood pressure devices.

Sample SphygmoCor[®] Parameters



Central Blood Pressure (SYS/DIA)



Brachial Blood Pressure (SYS/DIA)



Augmentation Index



Arterial Age (ArtyAge[™])



Central Pulse Pressure



Arterial Stiffness Factor (ASF[®])



SEVR Index (Heart Stress)



Exercise Capacity[®] (eCAP[®])



"Medical Grade" Heart Rate



Cardiac Efficiency (HPX[™])



Heart Stroke Volume



Heart Rate Variability (HRV+[™])

*Patented **SphygmoCor**[®] Transfer Function. Superior clinical insights due to proximity to major organs.



All “**Top 20 Hospitals**” use SphygmoCor technology to measure central blood pressure (cBP)



4000+ papers have been published in leading peer-reviewed journals like *Hypertension*, *Journal of Clinical Hypertension*, and the *Journal of the American College of Cardiology*



8 out of Top 10 Pharma companies have used SphygmoCor technology in their clinical trials



Over **11,000 patients** have been tested with SphygmoCor technology in pharmaceutical trials

Why Central Blood Pressure?



Medical/Professional Benefits

More precise determination of risk of cardiovascular, hypertension & related diseases, such as stroke, kidney disease, pre-eclampsia, cognitive decline/Alzheimer's.

Multiple "medical grade" arterial health insights beyond traditional blood pressure measurement.

More accurate identification of patients that are being over or undertreated for hypertensive related disorders (1.3B global hypertensives).

More precise targeting of prescription drugs, leading to overall cost savings (e.g. over-treatment, adverse effects).

More precise identification of "masked" and "white coat hypertension".

Economic impact due to potential unnecessary costs of medication and ongoing patient management (ABPM's etc).

Consumer Benefits

Central blood pressure and SphygmoCor® technology both enable **deep, medical grade health insights for multiple disease states and consumer health applications.**

Central Pressures Improve Prediction of CV Events

The Strong Heart Study of 3,500 high-risk adults showed that **central pulse pressure was 50% better than brachial pulse pressure in predicting cardiovascular events**

Roman MJ et al., Hypertension, 2007, 50:1-7.

In a study of 1,100 patients, **central pulse pressure was a powerful predictor of major cardiovascular events**, while brachial pressure was not.

Jankowski, P. et al. Hypertension 2008;51:848-855.




In a study of 400 elderly people, **central blood pressure demonstrated a superior prognostic performance** over brachial blood pressure

Pini, R et al., JACC 2008 51; 25:2432-9.

Irrespective of the brachial blood pressure status, central hypertension increased cardiovascular and cerebrovascular risk indicating the importance of controlling central hypertension”

Chang, et al, Hypertension

Other studies over a range of ethnic groups and diseases have shown that central pressure is an independent and more significant predictor of risk than conventional brachial blood pressure measurements



Application Across Multiple Disease States

“Beyond Blood Pressure”

“Beyond Hypertension”

Our technology extracts data that impacts multiple disease states beyond hypertension.



Actionable consumer & medical insights that drive better decision making and patient outcomes.

Application Across Multiple Device Platforms

Constant health insights integrated into your lifestyle - all with a single touch

ATCOR



Medical Devices

CONNECT

Consumer Wearables, Home Health & Clinical Care




CardieX

SphygmoCor®

Hardware Agnostic Health Analytics
"Touch Point™"

Connected Fitness



Peloton
Mirror
NordicTrack
LifeFitness

Consumer Devices



Sony
Nintendo
Microsoft

Smartwatches



Fitbit
Timex
Mobvoi
Fossil
Garmin
Apple

March 2022

Computers and Portable Technology



Apple
Microsoft
Lenovo
Hewlett-Packard

Our Competitive Moat

Established presence, market validation, and category focus give us a competitive stronghold.

Only Blood Pressure Devices that Allow Physician Reimbursement for Full Arterial Health Measurements

Robust Patent Portfolio

- Extensive patent portfolio covering critical components and applications for cuff and sensor methods.
- "World first" wearable sensor method - patent pending.

World Class Management & Engineering Team

- Diverse sector expertise. Multiple engineering staff 10+ years.
- World recognized scientific expertise and research pioneers.

Industry Leading Sector Expertise

- All "Top 20 Hospitals" use SphygmoCor® technology.
- 8 out of Top 10 Pharma companies have used SphygmoCor® in clinical trials.
- 46 clinical trials using SphygmoCor® with 35,000+ assessments.

Technology, Process Complexity & Focus

- Unreproducible algorithms, software, and process complexity for 20 years.
- Systematic documentation and protection of know-how, trade secrets, processes, and proprietary information.
- Specialized focus.

Research & Development

- 20+ years of R&D in non-invasive arterial health.
- 700+ PubMed references, 4000+ papers in peer-reviewed journals.

Pre-Existing Category Ownership

- "Category Inventor" of non-invasive central waveform analysis.
- FDA "predicate" device. Low regulatory risk for new devices.
- "Gold Standard" device/peer acknowledgement.

No direct competition in "world-first" devices and solutions in 2022/2023 CONNEQT product pipeline. Category creator in "vascular health".

CONNQ T Band Market Comparables At Scale

Market Opportunity

USD\$8.5B+

Arrhythmia



iRHYTHM

USD\$4.0B Mkt Cap

Market Opportunity

USD\$12B+

Continuous Blood Glucose Monitoring



Dexcom®

USD\$31.0B Mkt Cap

Market Opportunity

USD\$7B+

Pulse Oximetry Consumables



MASIMO

USD\$7.8B Mkt Cap

Market Opportunity

USD\$104B+

Blood Pressure and Heart Diagnostics



CONNQ T

\$Multi-Billion Mkt Opp

Oura Capital Raise (April 2022)
USD\$2.55B VALUATION



WHOOP Capital Raise (Aug 2021)
USD\$3.6B VALUATION



Our Operating Companies

Our two operating companies leverage our FDA-cleared and patented SphygmoCor® technology for specialized health market solutions - with separate go-to-market, brand, and sales strategy



ATCOR 



CONNEQT



Specialist Medical Devices and Data Solutions (B2B)

The only physician reimbursable medical devices cleared by the FDA to measure central arterial waveform pressure in all adults*

Medical Devices

SaaS Solutions

IP Licensing

14

Patents covering significant applications in cardiovascular health and consumer wearables

16

New trademarks filed internationally

Portfolio of company owned & jointly developed products:



XCEL SphygmoCor®

Gold standard for central blood pressure measurement



Oscar 2

ABPM technology joint collaboration with SunTech Medical on development, marketing and sales



Mobvoi TicWatch GTH Pro

Licensing of ATCOR health algorithms to Google-backed AI unicorn (Q1/CY22 launch)



Our Bluechip Customers

6 Continents / 34 Countries

4000+ Installs

All "US News" Annual Top 20 Hospitals

Selected by ARTERY Society to measure central blood pressure & arterial stiffness in the CARTESIAN Study - largest study to date on COVID and Hypertension

Research and pharmaceutical companies

For clinical trial services related to hypertension, cardiovascular disease, diabetes and renal disease



8 out of the Top 10 Pharma companies uses SphygmoCor® in their clinical trials.

Major IDNs and specialist physician practices

Cardiology, Nephrology and Endocrinology



4000+ papers have been published in leading peer-reviewed journals like *Hypertension*, *Journal of Clinical Hypertension*, and the *Journal of American College of Cardiology*.

Medical and consumer device licensing

Licensing algorithms and sale of technology



A track record of regulatory, reimbursement and commercial successes.

1500+


Gold standard technology used in 1500+ sites worldwide

9000+


46 trials conducted with 16 companies on 9000+ patients

700+

700+ PubMed references



Biopharma Studies using ATCOR PWA and PWW



Major Ongoing Trials and Studies

\$35K

System Revenues
Per Site ~ \$35,000

250+

Ongoing Global Research
Studies Currently in Process

>75%

Net Profit Margins
Per Site ~ >75%

\$6.9M

Clinical Trial Sales Pipeline
(Proposal/Closing) \$USD6.9M

ARTERY Society



CARTESIAN Study



World's largest study on hypertension and COVID-19

CARTESIAN aims to explore the immediate and long-term vascular consequences of COVID-19, and ATCOR's SphygmoCor® XCEL was selected to assess subjects' central pressure hemodynamics.

Andwin Scientific



Andwin Trial

Andwin is a 2022 initiated trial between Andwin Scientific, Syneos Health and cigarette and tobacco manufacturer, Philip Morris.

ATCOR's XCEL device is to be used in multiple endpoints for the trial including determination of clinically relevant arterial health outcomes based on aortic augmentation index (AIx) and arterial stiffness - key biomarkers of arterial health.

CC (Confidential)



CVD Trial

Specific Pharmacological Impacts on Cardiovascular Patients

Trial involves potentially 150 patients over a 26 month period to determine specific outcomes of novel therapies on cardiovascular disease patients. ATCOR's SphygmoCor® to be the primary outcome device for arterial health parameters.



“A complete remote patient monitoring, home, and clinical solution enabling a full spectrum of **medical grade** arterial diagnostics, driving better patient outcomes and actionable consumer health insights.”

“CONNEQT leverages **established technology** into “**world first**” **new solutions for existing partnerships** and healthcare customers.”

CONNQQT Expands Our Existing Proven Technology Into Significant New Markets.

One Platform – Multiple High-Value Use Cases



CONNQQT Ecosystem


A complete remote patient monitoring, home, and clinical solution.

On-Site Testing
Clinician-Facing

Remote Monitoring
Patient-Facing

CONNQQT
Cloud

PULSE
Home Use




CONNQQT
App



BAND
Wrist Wearable



PULSEMD
Professional Use



CONNQQT
Portal

World First Dual Sensor Medical Grade Wearable



CONNEQT Band/VitalWear™

CONNEQT Pulse



World First Consumer Dual Blood Pressure Monitor

CONNEXT Pulse

The **Only Remote Patient Monitoring** Solution that provides:

- Highest Billing Capability for Health Care Providers*.
- Complete Arterial Health Screening.
- Multiple Disease State Monitoring.
- Central Blood Pressure and SphygmoCor® Parameters.



Fully HIPPA Compliant

*RPM CPT Codes: 99453, 99454, 99457, 99458, 99091, SphygmoCor® Code 93050

Advance Praise for The Pulse

“ATCOR’s Pulse device has the potential to significantly improve treatment decisions by physicians and the health outcomes of patients through the use of advanced blood pressure and vascular health technologies.”

Hunter Champion, MD, PhD

Cardiologist
Southeastern Cardiology Associates

“ATCOR's “gold standard” blood pressure technology is now being made available to all healthcare providers and clinicians with the company's new Pulse device. The cardiovascular insights and accuracy obtained through ATCOR’s SphygmoCor technology are revolutionary, impactful and based on current scientific clinical studies regarding blood pressure and cardiovascular outcomes.”

Mark C. Houston MD MS

Director - Saint Thomas Medical Group, Saint Thomas Hospital,
Nashville, Tennessee

“ATCOR's market leading central aortic pressure technology has been the “gold standard” for over a decade with researchers, specialist clinicians, and pharmaceutical companies in their clinical trials. **The “Pulse” now launches that same technology into significant new healthcare markets giving physicians and patients alike deeper insights into cardiovascular health”**

Alberto Avolio

Professor Emeritus – Macquarie Medical School, Macquarie University.


“The Pulse enables healthcare practitioners to obtain unique cardiovascular health insights in order to inform better decision making around treatment. Importantly, **the Pulse is also the first device to target widespread adoption of arterial stiffness and central blood pressure as key indicators of cardiovascular health.**”

John R. Cockcroft

Dept Advanced Cardiology,
Columbia University Medical Centre,
New York

CONNQQT Product Launch Schedule


First FDA-cleared commercial product launch expected to begin late 2022. Additional products ramping throughout 2023



 FDA Regulatory Submission Complete

How We Make Money

Exponential new recurring revenue opportunities as products launch and scale.



Focus is on building **long-term “lifetime” customer value** through community and premium content delivery.

World Class Management Team with Track Record of Success



Craig Cooper
Chief Executive Officer

Boost Mobile
SoftBank
Saban Capital



Jarrod White
Chief Financial Officer

Traverse Accountants Pty Limited
Multiple listed entities



Mark Gorelick
Chief Product Officer

Traction Health
PAI Health
Performance Lab
Step Health



Jack Seitz
Chief Marketing Officer

WHOOOP
PUMA



Steven Keston
Chief Medical Officer

SKC Life Sciences
Uptake Medical
Pneuma Respiratory
Boehringer Ingelheim



Ahmad Qasem
Chief Science & Research Officer

PhD in Biomedical Engineering
Macquarie University



Chris Dax
President of ATCOR

Masimo
ISTA Pharmaceuticals
Elan Pharmaceuticals
Valeant



Lawrence Chan
Senior Director - Product Development & Engineering

Cochlear
Silverbrook Research



ZiHan Lin
Corporate & Business Development

Masimo
Uptake Medical
Harvard / Stanford



Susan Boekhoff
Head of Operations

walmart.com
T-Mobile



Lara Rosenbaum
Senior Director of Content Strategy

Fitbit
Hims
Rodale/Women's Health



Rhonda Welch
VP of Health Economics

Welch Healthcare Consulting
Biosense Webster, J&J
Baxter Healthcare

Board of Directors



Group CEO

CardieX/CONNEQT Health/
ATCOR Medical

Craig Cooper

Founding Partner - Softbank Capital
Co-Founder - Boost Mobile
Host - CNBC's "Adventure Capitalists"
Co-Founder - NRG Asia-Pacific
Head of Venture Capital and Digital Media - Saban Capital
Venture Partner - VantagePoint Capital Partners



Executive Chairman

Niall Cairns

Managing Partner - Kestrel Capital Pty Limited
Chairman - Tambla Limited
Director - Consolidated Financial Holdings Limited (ASX:CWL) DTS Limited, Harri LLC, Listing Logic Limited
Managing Partner - Kestrel Growth Funds
Managing Partner - Carnethy Evergreen Fund



Non-Executive
(Independent) Director

Lesa Musatto

Chief Marketing Officer - ATG
Chief Marketing and Strategy Officer - Backroads
Chief Commercial Officer - Nuelle
Safeway
Gap, Inc
Levi Strauss



Non-Executive
(Independent) Director

R. King Nelson

CEO - Q'Apel Medical, Inc
Director - Regenesys Biomedical
President, CEO & Director - Uptake Medical
Director - Digirad (NASDAQ:DRAD)
President, CEO & Director - Kerberos Proximal Solutions
President, CEO & Director - VenPro Medical (Medtronic)
Division President - Baxter Healthcare



Executive Director,
Chief Financial Officer

Jarrod White

Founding Partner - Traverse Accountants Pty Limited
Company Secretary - Multiple listed entities

Looking Forward

Near Term 2022 Goals

CardieX

- Uplist to NASDAQ/NYSE
- Drive investor interest in CDX in multi-billion dollar category

ATCOR

- Expand Pharma/clinical trials & research markets.
- One new CRO, HCP, & IDN partnership.
- Expand licensing and SphygmoCor OEM integrations.
- One new medical device, connected fitness, and consumer electronics partnership.
- Key leadership & sales hires.
- Expand Payer coverage & reimbursement.

CONNEQT

- Commence pre-launch marketing to consumer & healthcare channels.
- Build massive awareness/education around CONNEQT brand and category.
- Obtain FDA clearance - CONNEQT Pulse.
- Complete & lodge FDA application for CONNEQT Band.
- Complete CONNEQT Patient App and Clinician Portal.
- Launch eCommerce site for patient/consumer & clinical markets.
- Execute major health care provider & clinical partnerships for launch.
- Expansion of sales, marketing, & operations teams.

Thanks for Connecting

Craig Cooper

Chief Executive Officer
ccooper@cardiex.com

Niall Cairns

Executive Chairman
nccairns@cardiex.com

Mark Gorelick

Chief Product Officer
mgorelick@conneqthealth.com

Jack Seitz

Chief Marketing Officer
jseitz@conneqthealth.com

A. General Appendices

Cap Table and Top 20 Shareholders

CardieX Limited (ASX code: CDX)

Share Price ¹	A\$0.40	
Market Capitalisation ^{1, 2}	A\$44M	
Float ³ (75%)	A\$33M	
Capitalisation Table	No.	Insiders ³
Issued Shares^{1, 2}	110M	23%
Performance Shares (Directors) ⁴	16M	100%
Options (Management & Directors) ⁵	7M	9%
Fully Diluted Shares	133M	31%
Employees ¹	40	
Global HQ	Irvine, CA, USA	
Corporate and R&D	Sydney, Australia	

Notes:

1: As at 11 July 2022.

2: Market Capitalisation based on Issued Shares.

3: Insiders = Directors as at 11 July 2022.

4: Performance shares vest in tranches at share prices of \$1.20, \$1.50, \$2.00, \$2.50, & \$5.00 – Expiry date 31/12/2023.

5: Options exercise prices (\$0.50 & \$0.80) – Expiry dates in 2024, 2026, & 2027.

CardieX Top 20 Shareholders

1 C2 VENTURES PTY LIMITED	22,499,394
2 MR PAUL COZZI	6,000,000
3 MR PAUL JOSEPH COZZI	3,997,000
4 MR DARRYL PATTERSON & MRS MARGARET STEWART PATTERSON	2,616,559
5 MR MICHAEL JOHN KEIL & MRS JOANNE LEE KEIL	1,858,000
6 CB CO PTY LTD	1,547,000
7 CITICORP NOMINEES PTY LIMITED	1,542,643
8 BNP PARIBAS NOMINEES PTY LTD	1,425,135
9 MR HENDRIK HARTMANN & MS JIN KI PARK	1,250,000
10 TOWNS CORPORATION PTY LTD	1,124,147
11 MRS GLENIS NITA O'DONNELL	964,000
12 DOSSMAN PTY LTD	897,062
13 KEIL INVESTMENTS PTY LTD	877,000
14 DRUMNADROCHIT FUTURES PTY LTD	875,609
15 PLAUCS PTY LTD	825,000
16 SR MILJKOVIC SUPER PTY LTD	764,522
17 MR PHILIP WAYNE RIECK	737,517
18 MR JON PHILIPPE WEBSTER	736,486
19 MR DONALD O'DWYER & MRS JUDITH O'DWYER	659,491
20 DUNDRUM INVESTMENTS PTY LTD	615,000
Total	51,811,565
Balance of register	58,142,135

Financial Snapshot

(Full Financial Model and Projections Available Under NDA)

CardieX Limited Historical Financial Performance (A\$M)

Year (June 30)	FY19	FY20	FY21	FY22 (6m) Dec21
Revenue	3.9	4.3	5.0	2.1 ²
Growth		10%	17% ¹	N/A
GM	3.1	3.6	4.1	1.6 ²
GM%	79%	84%	82%	76% ^{2, 3}
EBITDA	(2.6)	(2.8)	(2.8)	(3.6)
Capital Raised	4.5	1.0	6.4	7.6 ²
Cash at Balance Date	4.9	2.1	3.7	5.5 ²
Total Assets	13.2	10.7	11.3	15.1 ²
Total Liabilities	6.3	4.8	3.4	3.5 ²
Shareholders Equity / NTA	7.0	5.9	7.9	11.6 ²

1: FY21 Revenue Growth – 32% in Constant Currency

2: FY22 financials are at half year – 31 December 2021

3: GM expected to be as per prior year for full year FY22

CONNQTM PULSE PARAMETERS

MEDICAL PARAMETERS

BRACHIAL SYSTOLIC BP
BRACHIAL DIASTOLIC BP
CENTRAL SYSTOLIC BP
BPVARIABILITY (BPV+[®])
ARTERIAL STIFFNESS INDEX (ASF[®])
EXERCISE CAPACITY[®] (eCAP[®])
HEART STRESS INDEX (HSXTM)
CENTRAL PULSE PRESSURE (VitalsRisk[®])
MEDICAL-GRADE HEART RATE (TruHR[®])



CONSUMER HEALTH PARAMETERS

ESTIMATED ARTERIAL AGE (ArtyAgeTM)
OVERALL HEART HEALTH INDEX (Arty[®] Score)
7-DAY BRACHIAL BP AVERAGE
30-DAY BRACHIAL BP AVERAGE
7-DAY CENTRAL SYSTOLIC BP AVERAGE

Powered By SphygmoCor[®]

Only Blood Pressure Device With
Unique CPT Reimbursement to
Physicians for In-Office Use.


2022/2023 PIPELINE

RESPIRATION RATE • BARORECEPTOR SENSITIVITY (BRS) • EJECTION FRACTION • CARDIAC OUTPUT • HEART PERFORMANCE INDEX[®] (HPX[®])
VO2 MAX EQUIVALENT • STROKE VOLUME • ARTERIAL RESISTANCE • HEART FAILURE RISK INDICATOR • CARDIORESPIRATORY FITNESS
INDEX • HEART STROKE VOLUME • ATRIAL FIBRILLATION (AFIB)

CONNQTM BAND PARAMETERS

CLINICAL GRADE HEALTH PARAMETERS

BRACHIAL BLOOD PRESSURE (BBP)
 CENTRAL BLOOD PRESSURE (CBP)
 24-HR BBP+CBP VARIABILITY
 MEDICAL-GRADE HEART RATE (TruHR[®])
 ARTERIAL STIFFNESS INDEX (ASF[®])
 ESTIMATED ARTERIAL AGE (ArtyAgeTM)
 SUB-ENDOCARDIAL VIABILITY (eCAP[®])
 HEART STRESS/AUGMENTATION INDEX (HSXTM)
 CENTRAL PULSE PRESSURE (VitalsRisk[®])
 OVERALL HEART HEALTH INDEX (Arty[®] Score)
 FDA CLEARANCE (PENDING)
 CPT CODE FOR REIMBURSEMENT



CONSUMER HEALTH PARAMETERS

CONTINUOUS HEART RATE
 RESTING HEART RATE
 HEART RATE VARIABILITY (TruHRV[®])
 OXYGEN SATURATION (SpO₂)
 ENERGY EXPENDITURE
 VO₂ MAX ESTIMATION
 VO₂ CONTINUOUS MEASUREMENT
 LACTATE THRESHOLD
 SLEEP PHASES (LIGHT, DEEP, WAKE)
 EPOC ANALYSIS
 STEPS TRACKING
 ACTIVITY EFFORT SUMMARY
 ACTIVITY INTENSITY CLASSIFICATION (LOW, MODERATE, HIGH)

Only Wearable Device With **Unique CPT Reimbursement** for Physicians

Most Fully Featured **Medical Grade** Health Wearable


2023/2024 PIPELINE

FITNESS IMPACT • BODY READINESS • DAILY STRESS AND RECOVERY TRACKING • FITNESS LEVEL INDEX
 DAILY ACTIVITY LEVEL RECOMMENDATIONS • A.FIB RISK SCREENING • SLEEP RESPIRATION • SLEEP APNEA RISK SCREENING

CONNEQT Digital Companions

For Pulse and CONNEQT Band

CONNEQT App Consumer




- Health parameter dashboard with historical view and trends.
- Arty heart health AI coaching and recommendations.
- Data sharing with friends, family, and care provider.
- Apple HealthKit & Google Fit integration.
- Lifestyle disease coaching programs.
- Monthly heart health physician reporting.
- Lifestyle tele-coaching care team.

CONNEQT Cloud



- Secure and private storing and sharing of CONNEQT product data
- Account management and authentication
- HIPPA and FDA compliant
- ArtyAI Engine backend
- Cloud Analytics

CONNEQT Portal Physicians, HCP's, and Clinical Partners



- Patient management
- Remote and in-office Patient Monitoring Dashboard
- CPT Reimbursement Documentation Support
- Decentralised Clinical Trial Management
- Customized Patient Notifications

CONNNECT Use Cases

Use Case for Pharma/Medtech


Using cBP measurements in decentralized clinical trials to improve product development

Strategy: Utilization of cBP parameters in clinical trials supporting safety and efficacy endpoints.

Value:

- Clinically established and accepted cBP parameters.
- Decentralized options.

Powered by the CONNEQT Cloud, the CONNEQT device and data management system for decentralized clinical trials reduces costs, accelerates patient recruitment, and increases the patient pool.




Use Case for Healthcare Providers

Helps Providers access more in-depth, real-time patient data and improve risk assessment and clinical decision making.

The global RPM market is on pace to reach **\$117.1 billion by 2025**, compared to **\$23.2 billion in 2020** – more than a fivefold increase in just five years.

Source: [Forbes Communication Council](#)

*RPM CPT Codes: 99453, 99454, 99457, 99458, 99091



Create better vascular health outcomes through stronger physician-patient relationships, meaningful data and precision technology.

Consumers/ Home Use Case

Home health monitoring and medical grade wearable for the world's largest health markets




PULSE
Home Use



BAND
Wrist Wearable

CONNQQT
App



Empowering consumers to make **better decisions** about their health by giving them access to medical grade data.

References

Total Addressable Market
and Population Size

1. World Health Organization. https://www.who.int/health-topics/cardiovascular-diseases/#tab=tab_1
2. Fortune Business Insights. <https://www.fortunebusinessinsights.com/industry-reports/blood-pressure-monitors-market-100059>
3. Industry Status Report. <https://industrystatsreport.com/Lifesciences-and-Healthcare/Medical-Wearables-Market-Size-and-Growth/Summary>
4. Valuates Reports. <https://reports.valuates.com/market-reports/QYRE-Othe-0A163/digital-health-market>
5. Grand View Research. <https://www.grandviewresearch.com/press-release/global-digital-health-market>
6. Journal of American Society of Hypertension. <https://www.sciencedirect.com/science/article/abs/pii/S193317116304892?via%3Dihub>
7. The Hospitalist. <https://www.the-hospitalist.org/hospitalist/article/220457/coronavirus-updates/comorbidities-rule-new-yorks-covid-19-deaths>

Disclaimer

- **Disclaimer for Presentation** - The following disclaimer applies to this presentation (**Presentation**). This presentation has been prepared by CardieX Limited ACN 113 252 234 (**Company**).
 - **Summary information** - This Presentation contains summary information about the Company and its subsidiaries (**Group**) and their activities which is current only as at the date of this Presentation. The information in this Presentation is of a general nature. This Presentation should also be read in conjunction with the Company's other periodic and continuous disclosure announcements lodged with ASX, which are available at www.asx.com.au.
 - **Not investment advice** - The information contained in this Presentation is not financial product, investment, legal, taxation or other advice or any recommendation to acquire securities in the Company. No reliance may be placed for any purpose whatsoever on the information contained in this Presentation. This presentation does not and will not form any part of any contract for the acquisition of securities in the Company.
 - **Investment risk** - An investment in securities in the Company is subject to investment and other known and unknown risks, some of which are beyond the control of the Group. The Company does not guarantee any particular rate of return or the performance of its securities, nor does it guarantee any particular tax treatment. You should carefully consider the risks outlined in this Presentation and consult a professional advisor before making an investment decision.
 - **Past performance** - Past performance information, including past share price performance, given in this Presentation is given for illustrative purposes only and should not be relied upon as an indication of future performance.
 - **Future performance** - This Presentation contains forward looking statements, including statements regarding the Company's intentions, beliefs or current expectations about the Group's business and operations, and market conditions. Forward looking statements can generally be identified by the use of forward looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target" and other similar expressions. Estimates of, indications of, and guidance or outlook on, future earnings or financial position or performance are also forward looking statement. Forward looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee or future performance. Forward looking statements involve known and unknown risks, uncertainties, assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends which are based on interpretations of current market conditions.
- Actual results, performance or achievements may vary materially from any forward looking statements and the assumptions on which statements are based. Except as required by law or regulation, the Group disclaims all obligations to update publicly any forward looking statements, whether as a result of new information, future events or results or otherwise.
- **Financial information** - All dollar values are in Australian dollars, unless otherwise stated. This Presentation contains pro forma financial information. The pro forma financial information has been prepared by the Company in accordance with the measurement and recognition requirements, but not the disclosure requirements, of applicable accounting standards and other mandatory reporting requirements in Australia.
 - **Third party information** - Certain market and industry data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither the Group nor its representatives have independently verified any such market or industry data provided by third parties or industry or general publications. No representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy.
 - **Disclaimer** - To the maximum extent permitted by law, the Group and its advisers expressly disclaim all liabilities and responsibility in respect of any expenses, losses, damages or costs incurred by any recipient as a result of the use or reliance on anything contained in or omitted from the information in this Presentation, including, without limitation, any liability arising from fault or negligence or otherwise, and make no representation or warranty, express or implied, as to the fairness, currency, accuracy, reliability or completeness of the information contained in this Presentation. Not for release or distribution in the United States of America - This Presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. This Presentation may not be distributed or released in the United States. Securities in the Company have not been, nor will be, registered under the U.S. Securities Act of 1933, as amended (U.S. Securities Act) or the securities laws of any state or other jurisdiction of the United States. Accordingly, the securities in the Company may not be offered or sold, directly or indirectly to, persons in the United States or persons who are acting for the account or benefit of a person in the United States unless they have been registered under the U.S. Securities Act (which the Company has no obligation to do so or procure) or in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and any other applicable U.S. state securities laws.
 - **The release of this presentation was authorised by the Board of Directors of the Company**